UK - MSIF provides blood testing technology company with £100,000 investment
Merseyside Special Investment Fund has backed PalindromX, a blood testing technology company, with ТЃ100,000 of seed funding through its Liverpool Seed Fund. PalindromX is a spinout from the University of Liverpool. It has developed a patented technology that increases the sensitivity of blood testing. The technology gives a quicker and more accurate diagnosis that enables a more appropriate and timely treatment. It also significantly reduces costs by allowing doctors to run tests for several different substances simultaneously.
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Czech Republic-headquartered family office is targeting DACH and CEE region deals
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Ex-Rocket Internet leader Bettina Curtze joins Swiss VC firm as partner and CFO
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Estonia-registered VC could bolster LP base with fresh capital from funds-of-funds or pension funds








